$LTRN News

Lantern Pharma Reports Clinical Data And Updates From Ongoing Phase 2 HARMONIC Trial Evaluating LP-300 In Combination With Carboplatin And Pemetrexed In Patients With EGFR Exon 21 L858R-Mutant NSCLC

Lantern Pharma Receives Successful Response To Its Recent FDA Type C Meeting Request Focused On The Ongoing Phase 2 HARMONIC Trial Of LP-300 In Never-Smokers With Advanced Non-Small Cell Lung Cancer Adenocarcinoma

Lantern Pharma Q1 EPS $(0.30) Beats $(0.36) Estimate

Lantern Pharma Announces Up To $9.25M Direct Offering With Existing Shareholders And Unnamed Institutional Investor; Transaction Expected To Close May 14

Lantern Pharma Inc. (LTRN) Discusses Live Demonstration of withZeta.ai AI Platform for Rare Cancer Drug Discovery Transcript

Lantern Pharma Inc. (LTRN) Discusses Live Demonstration of withZeta.ai Platform for AI-Driven Oncology Drug Discovery Transcript

Lantern Pharma Expands Its predictBBB.ai Web Service Into A Large Quantitative Model

Lantern Pharma Plans First Public Demonstration Of withZeta.ai, Its Multi-Agentic AI Co-Scientist Platform On April 30

Lantern Pharma shares are trading higher after the company announced that it scheduled an FDA Type C meeting to refine the HARMONIC trial for its LP-300 lung cancer drug.

Lantern Pharma shares are trading higher after the company announced that it scheduled an FDA Type C meeting to refine the HARMONIC trial for its LP-300 lung cancer drug.

Lantern Pharma Schedules FDA Type C Meeting To Refine HARMONIC Trial For LP-300 In EGFR L858R NSCLC, Highlighting Progression-Free Survival Signals

Lantern Pharma Inc. (LTRN) Shareholder/Analyst Call Transcript

Lantern Pharma Inc (LTRN) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial ...

Lantern Pharma Invites Investors, Analysts & Shareholders to Experience the Future of Drug Discovery via a Live Demo of withZeta.ai — the World's First Multi-Agentic Co-Scientist for Rare Cancers — 8:30 AM Eastern, April 9, 2026

Lantern Pharma shares are trading higher after the company reported better-than-expected Q4 financial results.

Lantern Pharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Lantern Pharma Inc. 2025 Q4 - Results - Earnings Call Presentation

Lantern Pharma Inc. (LTRN) Q4 2025 Earnings Call Prepared Remarks Transcript

Lantern Pharma Q4 EPS $(0.36) Beats $(0.46) Estimate

Why Is Lantern Pharma Stock Soaring Monday?